MetaVia is trading at $1.22, up 7.02% in pre-market, with no confirmed cause for the rise.
- On October 28, MetaVia said Phase 1 DA-1726 data on MRI-PDFF, weight loss and lean-mass preservation will be presented orally at the November 4 Precision Liver Symposium.
- No source located links the announcement to the rise. Broader futures were mixed, with technology weakness, so market sentiment does not clearly explain the move.
- The latest prior company update located was the October 13 appointment of its chief medical officer.